PFM Health Sciences LP Sells 93,013 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

PFM Health Sciences LP decreased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 54.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,387 shares of the biopharmaceutical company’s stock after selling 93,013 shares during the quarter. PFM Health Sciences LP’s holdings in Intra-Cellular Therapies were worth $5,662,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Avoro Capital Advisors LLC grew its stake in shares of Intra-Cellular Therapies by 21.2% in the 2nd quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock worth $205,470,000 after acquiring an additional 525,000 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in shares of Intra-Cellular Therapies by 62.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock worth $117,557,000 after buying an additional 661,052 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of Intra-Cellular Therapies by 11.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,159,356 shares of the biopharmaceutical company’s stock worth $84,830,000 after buying an additional 116,494 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Intra-Cellular Therapies by 214.5% in the 2nd quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock worth $60,895,000 after buying an additional 606,358 shares during the last quarter. Finally, Eagle Asset Management Inc. boosted its holdings in shares of Intra-Cellular Therapies by 130.5% in the 3rd quarter. Eagle Asset Management Inc. now owns 624,759 shares of the biopharmaceutical company’s stock worth $45,714,000 after buying an additional 353,723 shares during the last quarter. Institutional investors own 92.33% of the company’s stock.

Insider Buying and Selling

In related news, President Michael Halstead sold 22,869 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.60% of the stock is owned by company insiders.

Intra-Cellular Therapies Stock Down 1.1 %

Shares of ITCI opened at $85.65 on Friday. The business’s 50-day moving average price is $80.27 and its 200-day moving average price is $75.42. Intra-Cellular Therapies, Inc. has a twelve month low of $58.92 and a twelve month high of $93.45. The stock has a market cap of $9.08 billion, a PE ratio of -98.45 and a beta of 0.97.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $175.40 million for the quarter, compared to the consensus estimate of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company’s quarterly revenue was up 39.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.25) earnings per share. Analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ITCI shares. Needham & Company LLC reissued a “buy” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, October 30th. Royal Bank of Canada boosted their price target on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Piper Sandler raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $68.00 to $92.00 in a report on Friday, September 6th. Morgan Stanley upped their price objective on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, September 16th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $97.23.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.